IL89388A - Preparations containing reliable idols are converted to halogen, several such compounds and a process for their preparation - Google Patents

Preparations containing reliable idols are converted to halogen, several such compounds and a process for their preparation

Info

Publication number
IL89388A
IL89388A IL8938889A IL8938889A IL89388A IL 89388 A IL89388 A IL 89388A IL 8938889 A IL8938889 A IL 8938889A IL 8938889 A IL8938889 A IL 8938889A IL 89388 A IL89388 A IL 89388A
Authority
IL
Israel
Prior art keywords
group
chloro
hydrogen
allylamine
fluoro
Prior art date
Application number
IL8938889A
Other languages
English (en)
Hebrew (he)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of IL89388A publication Critical patent/IL89388A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL8938889A 1988-02-25 1989-02-23 Preparations containing reliable idols are converted to halogen, several such compounds and a process for their preparation IL89388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16036488A 1988-02-25 1988-02-25
US16038288A 1988-02-25 1988-02-25

Publications (1)

Publication Number Publication Date
IL89388A true IL89388A (en) 1995-03-15

Family

ID=26856831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8938889A IL89388A (en) 1988-02-25 1989-02-23 Preparations containing reliable idols are converted to halogen, several such compounds and a process for their preparation

Country Status (17)

Country Link
EP (1) EP0330218B1 (pt)
JP (1) JP2772660B2 (pt)
KR (1) KR890012641A (pt)
CN (1) CN1035497A (pt)
AT (1) ATE117549T1 (pt)
AU (1) AU618076B2 (pt)
CA (1) CA1338647C (pt)
DE (1) DE68920757T2 (pt)
DK (1) DK89489A (pt)
ES (1) ES2070134T3 (pt)
FI (1) FI890827A (pt)
GR (1) GR3015470T3 (pt)
IE (1) IE65553B1 (pt)
IL (1) IL89388A (pt)
NO (1) NO890801L (pt)
NZ (1) NZ228068A (pt)
PT (1) PT89839B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ssao/vap−1のハロアリルアミン阻害剤およびその用途
CA2977947A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
GB201602934D0 (en) * 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
US20200069648A1 (en) * 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
WO2024044813A1 (en) * 2022-08-29 2024-03-07 Pharmaxis Ltd. Novel selective inhibitors of lysyl oxidases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891064A (en) * 1956-05-28 1959-06-16 Dow Chemical Co 3, 3-dichloro-2-methylallylamines
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
DD246990A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gamma-chlorallylverbindungen aus polychloralkanen

Also Published As

Publication number Publication date
AU618076B2 (en) 1991-12-12
JPH023626A (ja) 1990-01-09
GR3015470T3 (en) 1995-06-30
FI890827A (fi) 1989-08-26
EP0330218A3 (en) 1992-01-02
PT89839B (pt) 1994-04-29
IE890612L (en) 1989-08-25
AU3016089A (en) 1989-08-31
KR890012641A (ko) 1989-09-18
CN1035497A (zh) 1989-09-13
EP0330218B1 (en) 1995-01-25
CA1338647C (en) 1996-10-15
FI890827A0 (fi) 1989-02-21
NO890801D0 (no) 1989-02-24
NO890801L (no) 1989-08-28
DK89489D0 (da) 1989-02-24
NZ228068A (en) 1991-11-26
ES2070134T3 (es) 1995-06-01
DE68920757D1 (de) 1995-03-09
EP0330218A2 (en) 1989-08-30
IE65553B1 (en) 1995-11-01
DE68920757T2 (de) 1995-06-08
DK89489A (da) 1989-08-26
PT89839A (pt) 1989-10-04
ATE117549T1 (de) 1995-02-15
JP2772660B2 (ja) 1998-07-02

Similar Documents

Publication Publication Date Title
US5021456A (en) Inhibitors of lysyl oxidase
US4965288A (en) Inhibitors of lysyl oxidase
US5182297A (en) Inhibitors of lysyl oxidase
US5252608A (en) Inhibitors of lysyl oxidase
US4943593A (en) Inhibitors of lysyl oxidase
US5059714A (en) Inhibitors of lysyl oxidase
US5120764A (en) Inhibitors of lysyl oxidase
AU782759B2 (en) Composition comprising a tramadol material and an anticonvulsant drug
EP0678026B1 (fr) Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
US7902251B2 (en) Method for treating pain
EP1415667B1 (en) Pancreatic juice secretion regulators comprising lpa receptor controller
IL89388A (en) Preparations containing reliable idols are converted to halogen, several such compounds and a process for their preparation
JP2001506978A (ja) 置換1―[2[ビス(アリール)メトキシ]エチル]―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用
WO2008020651A1 (fr) antagoniste de récepteur P2X4
US20070088073A1 (en) Method for treating pain
KR101701943B1 (ko) 당뇨병의 치료 또는 예방약
JP5810099B2 (ja) 5−ht(2b)受容体でアンタゴニスト活性を有する高選択性5−ht(2c)受容体アゴニスト
AU608922B2 (en) Method for the treatment of anxiety
JPH10511978A (ja) アルツハイマー病の治療用薬剤
US20070105940A1 (en) Method for treating pain
US20070259945A1 (en) Method for treating pain
RU2349587C2 (ru) Производное фенилуксусной кислоты и его применение
FR2763847A1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
JP6461922B2 (ja) アミロイド線維形成の抑制又は阻害剤
MXPA06004390A (es) Tratamiento de combinacion de obesidad que implica derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 e inhibidores de lipasa.

Legal Events

Date Code Title Description
KB Patent renewed
RH1 Patent not in force
HC Change of name of proprietor(s)

Owner name: AVENTIS INC.

Free format text: FORMER NAME:MERRELL PHARMACEUTICALS INC.